MISSISSAUGA, ON, June 17, 2021 /CNW/ - Sanofi Canada announced today that a new 300 mg single-dose (single-use) pre-filled pen for DUPIXENT ® (dupilumab injection) is now available in Canada. The ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won expanded U.S. approval for its best-selling Dupixent injection to treat ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved their Dupixent injection for the treatment of adult patients ...

Dupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the diseases driven by type 2 inflammation Atopic dermatitis is a chronic inflammatory disease that ...

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published detailed positive results ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...

Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...

This approval was based on findings from two clinical studies conducted in adult patients already receiving maximal standard-of-care inhaled therapy. The BOREAS and NOTUS studies showed a 30% and 34% ...